Toripalimab, Bevacizumab, and Chemo Elicits Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.
Final Analysis of Niraparib Does Not Show Significant OS Benefit in Recurrent Ovarian CancerMarch 27th 2023
In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.
Considering Targeted Therapies When Managing Young Patients With mCRCMarch 27th 2023
In an interview with Targeted Oncology, Jennifer Y. Wo, MD, highlighted emerging discussions in the metastatic colorectal cancer space, where targeted therapies play a role, and what the next steps for research include.
Clinical Benefit Seen With Olaparib/Selumetinib in RAS-Mutated Ovarian and Endometrial CancersMarch 27th 2023
The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.
GCLQ and LELSQ Shows Similar Total Scores in Assessment of Lymphedema in Endometrial CancerMarch 27th 2023
A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian CancerMarch 27th 2023
The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian CancerMarch 26th 2023
According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.
When to Use Second-Line CAR T-cell Therapy for Relapsed/Refractory DLBCLMarch 24th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.
Ruxolitinib Extended-Release Could Mitigate Risk/Increase Compliance for Patients With MPNsMarch 24th 2023
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, provided an in-depth discussion on the complete response letter issued to ruxolitinib extended-release, and why continued evaluation of the agent could be beneficial for patients with MPNs.
Personalizing Therapies for Optimal Outcomes in Multiple MyelomaMarch 24th 2023
In an interview with Targeted Oncology, Paul Richardson, MD, highlighted his presentation from the 4th Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies on updates and personalization of treatments for patients with multiple myeloma.
FDA Issues Complete Response Letter to Ruxolitinib XR Tablets for MPNsMarch 24th 2023
The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in a complete response letter.
Abbas Assesses the Use of Allogenic Transplant In MPNsMarch 23rd 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
ASCT Shows No OS Effects vs Maintenance Rituximab After BR or R-CHOP in MCLMarch 23rd 2023
Clinical trials exploring regimens without ASCT consolidation in young patients with MCL are needed, and maintenance with rituximab should be considered for patients after first-line treatment with bendamustine plus rituximab and R-CHOP